Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
Antimicrobial Proteins01:23

Antimicrobial Proteins

1.1K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
1.1K
Antibody Actions01:26

Antibody Actions

1.2K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.2K
Humoral Immune Responses01:36

Humoral Immune Responses

73.3K
Overview
73.3K
Complementation Tests00:49

Complementation Tests

5.0K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
5.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety.

HemaSphere·2026
Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026
Same author

Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.

Annals of hematology·2026
Same author

Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study.

American journal of hematology·2026
Same author

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

American journal of hematology·2026
Same author

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

American journal of hematology·2026

Related Experiment Video

Updated: Jul 26, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K

Molecular pharmacology in complement-mediated hemolytic disorders.

Marta Bortolotti1,2, Wilma Barcellini1, Bruno Fattizzo1,2

  • 1Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

European Journal of Haematology
|June 12, 2023
PubMed
Summary

Novel complement-targeted therapies are revolutionizing hemolytic disorders like PNH and CAD. These advanced treatments offer improved outcomes for paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated anemias.

Keywords:
atypical hemolytic uremic syndromecold agglutinin diseasecomplement inhibitorsparoxysmal nocturnal hemoglobinuriawarm autoimmune hemolytic anemia

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Related Experiment Videos

Last Updated: Jul 26, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.7K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Complement-mediated hemolytic disorders, including PNH, CAD, AIHA, and aHUS, have seen a paradigm shift from supportive care to targeted therapies.
  • Advances in understanding complement pathway pathogenesis have enabled the development of novel therapeutic strategies.
  • These targeted therapies have significantly improved patient management, survival rates, and quality of life.

Purpose of the Study:

  • To review novel, clinically relevant therapies for complement-mediated hemolytic anemias.
  • To highlight current and emerging treatments for paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease (CAD), autoimmune hemolytic anemia (AIHA), and atypical hemolytic uremic syndrome (aHUS).

Main Methods:

  • Review of current literature on complement-targeted therapies for hemolytic anemias.
  • Focus on therapies with established clinical practice readiness and those under active investigation.
  • Analysis of drug mechanisms targeting various points in the complement cascade.

Main Results:

  • C5 inhibitors (eculizumab, ravulizumab) are standard for PNH; C3 inhibitor pegcetacoplan is an option for non-responders.
  • Sutimlimab (anti-C1s antibody) shows significant efficacy in CAD, with broader regulatory approval anticipated.
  • Pegcetacoplan and ANX005 are being investigated for AIHA; complement inhibitors are approved for aHUS, with novel agents in development.

Conclusions:

  • Complement-targeted therapies represent a major advancement in managing hemolytic anemias.
  • Several novel agents targeting different complement pathways are in development, offering future treatment options.
  • Personalized therapeutic strategies based on complement pathway involvement are becoming increasingly important.